Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.45 AUD
Change Today +0.01 / 2.30%
Volume 84.7K
As of 9:30 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Open
A$0.44
Previous Close
A$0.44
Day High
A$0.45
Day Low
A$0.44
52 Week High
09/4/14 - A$0.65
52 Week Low
02/13/15 - A$0.38
Market Cap
186.1M
Average Volume 10 Days
265.2K
EPS TTM
A$-0.03
Shares Outstanding
418.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials and Phase I multiple ascending dose trials for the treatment of generalized anxiety disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers's disease; BNC101, a monoclonal antibody, which has completed preclinical studies that targets cancer stem cells; and BNC105, a novel compound to disrupt the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has collaboration agreement with Merck & Co. to develop compounds targeting cognitive impairment in conditions, such as ADHD, alzheimer’s disease, parkinson’s disease, and schizophrenia. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (BNO) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$483.8K
Chief Financial Officer
Total Annual Compensation: A$165.7K
Chief Medical Officer
Total Annual Compensation: A$433.5K
Legal Counsel and Company Secretary
Total Annual Compensation: A$45.8K
Chief Scientific Officer
Total Annual Compensation: A$47.2K
Compensation as of Fiscal Year 2015.

bionomics ltd (BNO) Key Developments

Bionomics Ltd. Announces Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate

Bionomics Limited announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA). The company plans to initiate a Phase 1 clinical trial in patients with metastatic colon cancer and in patients with metastatic pancreatic cancer prior to 31 December 2015. BNC101 is a high affinity humanized monoclonal antibody targeting cancer stem cells. LGR5 is a receptor over expressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours. BNC101causes internalization of LGR5, blocking cancer stem cell and Wnt signaling. In preclinical studies BNC101 prevents or delays tumour recurrence, and reduces cancer stem cells as single agent and in combination with standard chemotherapy treatment. Furthermore, BNC101 reduces circulating tumour cells that express LGR5. In IND-enabling studies, BNC101 was well tolerated at doses up to 150 mg/kg in both male and female cynomolgus monkeys in 28-day repeat dose study and an adverse event dose has not been identified. The Phase 1 program will aim to demonstrate that BNC101 is safe and well tolerated and that it is able to delay disease relapse in optimally treated patients. Initial indications will be metastatic colorectal cancer and metastatic pancreatic cancer. Initial development will occur as a combination therapy with standard of care chemotherapies while long term development strategies will evaluate adjuvant or maintenance therapy with first line therapies to prevent or delay tumour relapse.

Bionomics Ltd. Reports Audited Group Earnings Results for the Year Ended June 30, 2015

Bionomics Ltd. reported audited group earnings results for the year ended June 30, 2015. For the period, the company's net operating and investing cash outflows for the period increased by 137% to AUD 4,639,331, revenue from ordinary activities decreased by 65% to AUD 6,827,277, revenue and other income decreased by 40% to AUD 16,616,405, compared with AUD 27,545,996 for the period to 30 June 2014 and loss from ordinary activities after tax attributable to members decreased by 629% to AUD 16,949,405. The current year loss reflects the Company's investment in research and development activities. The operating loss after tax of the Group for the period was AUD 16,949,405 and reflects the Company's continued execution of its business plan.

Bionomics Limited Appoints Tony Colasin as Chief Business Officer

Bionomics Limited announced the appointment of Tony Colasin as Chief Business Officer. Based in San Diego, California, Mr. Colasin will lead corporate development including business development and strategic opportunities. He joins Bionomics from Ironwood Pharmaceuticals, where he served as Vice President of Corporate Development and was responsible for strategy and tactical oversight of in-licensing, and mergers and acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.45 AUD +0.01

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies
 

Industry Analysis

BNO

Industry Average

Valuation BNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.0x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.